Benchling for RNA Therapeutics R&D
Benchling
Oct 20, 2021
Abstract
Because RNA therapeutics can target conditions that small molecules and proteins cannot address, researchers are now on the verge of treating previously “undruggable” diseases. From the approval of the first antisense oligonucleotide, aptamer, and siRNA, to the now famous launch of mRNA-based COVID-19 vaccines, the pipeline of RNA therapies and vaccines has expanded dramatically. However, as RNA therapeutics have gained traction scientifically and clinically, the software tools to engineer them have been frustratingly limited. This application note discusses complexities in RNA therapeutics R&D as well as how Benchling can help overcome these hurdles.
Application File
Benchling for RNA Therapeutics R&D.pdf
Latest Protocols
- Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease
- High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene
Comments
Be the first to comment.